Has Lambros Stamatakis, MD received payments from drug or device companies?

Yes. Drug and device makers reported $39,316 in general payments to Lambros Stamatakis, MD across 88 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Lambros Stamatakis, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Lambros Stamatakis, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Lambros Stamatakis, MD

Urology · Washington, DCNPI 1962641332

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $28,300 of the $39,316 with a category attached, or 72.0%. 24 manufacturers reported payments, led by Ferring Pharmaceuticals Inc. at 53.4% of the total. 2025 is the largest year on record at $30,277, more than ten times the $162 reported in 2019. Among urology clinicians in DC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$39,316in general payments, 2019–2025

Across 88 payments — averaging $446.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Ferring Pharmaceuticals Inc.$21K
Immunitybio, Inc.$5K
Urogen Pharma, Inc.$4K
Merck$3K
Janssen Global Services, LLC$2K
Janssen Scientific Affairs, LLC$2K
plus $2K from 18 others

$953,109in research payments, 2019–2025

Across 68 payments — averaging $14,016 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Merck$953K

What the payments were for

Consulting fees$4,55812%
Speaking & faculty fees$28,30072%
Travel & lodging$3,1578%
Food & beverage$3,3028%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Ferring Pharmaceuticals Inc.	18	$21,005
Immunitybio, Inc.	7	$5,465
Urogen Pharma, Inc.	4	$3,762
Merck	14	$2,552
Janssen Global Services, LLC	8	$2,332
Janssen Scientific Affairs, LLC	4	$2,043
Procept Biorobotics Corporation	5	$1,015
Axonics, Inc.	2	$316
Johnson & Johnson(2 entities)	6	$230
Photocure Inc	2	$155
Progenics Pharmaceuticals, Inc.	2	$54
Antares Pharma, Inc.	2	$52
Pfizer	2	$51
Boston Scientific	2	$37
Intuitive Surgical	1	$36
Sumitomo Pharma America, Inc.	1	$33
Sanofi	1	$32
Novartis	1	$32
Coloplast	1	$23
Olympus America Inc.	1	$21
180 Medical, Inc.	1	$21
Teleflex LLC	1	$20
Myovant Sciences Inc.	1	$15
Cook Medical LLC	1	$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$39,316 in reported general payments places this provider in the 95th percentile of 47 urology providers in District of Columbia.

See all urology providers in District of Columbia →

Medicare billing

Part B allowed, 2024

$204,003

Medicare patients

450

Services billed

1,278

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Tamsulosin Hcl	85	$1,443
Finasteride	23	$542
Oxybutynin Chloride ErOxybutynin Chloride	12	$271

Paid to pharmacies, not to this prescriber.

Other urology in Washington

Armine SmithWashington$58K
Nathan ShawWashington$54K
Patrick MufarrijWashington$31K
Ryan HankinsWashington$29K
Adam MetwalliWashington$27K
Michael WhalenWashington$17K
Pamela ColemanWashington$14K
Leslie DeaneWashington$13K
Jason EngelWashington$12K
Keith KowalczykWashington$11K

See the full list for District of Columbia →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →